Application of ackermania muciniphila in relieving hyperuricemia

A hyperuricemia and proteinophilic technology, applied in the field of microorganisms, can solve problems such as the effects of high uric acid that have not been studied, and achieve the effect of promoting the health of mice, maintaining the intestinal barrier, and reducing the pain of patients

Pending Publication Date: 2022-07-29
DALIAN POLYTECHNIC UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Akkermansia muciniphila is an emerging intestinal probiotic in recent years. It plays an excellent role in the treatment of enteritis, diabetes, and cardiovascular and cerebrovascular diseases. However, no one has studied its impact on high uric acid. The means of treating hyperuricemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ackermania muciniphila in relieving hyperuricemia
  • Application of ackermania muciniphila in relieving hyperuricemia
  • Application of ackermania muciniphila in relieving hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1: Cultivation of Akkermansia muciniphila

[0039] (1) Purified mucin

[0040] The mucin was purchased from Sigma Reagent Company, the product number is M2378 (100g). The mucin was purified by the method of alcohol precipitation, and 12.5 g of mucin powder could obtain 100 mL of purified mucin.

[0041] (2) strain recovery

[0042] The purchased Akkermansia muciniphila ATCC BAA-835 was added to BHI medium containing 10% mucin and 0.03% L-cysteine ​​at 37°C in an anaerobic environment (N 2 / CO 2 80:20v / v) activated for 48h.

[0043] (3) Bacteria culture

[0044] The bacterial liquid obtained in step (2) was centrifuged (8000g / min, 10min), repeated twice, and the bacterial species was resuspended with sterile PBS, added to the BHI medium in an equal amount, and at 37° C. under an anaerobic environment ( N 2 / CO 2 80:20v / v) cultured for 48h, the number of cells obtained is ≥10 8 CFU / mL of Akkermansia muciniphila culture. The obtained culture solution was c...

Embodiment 2

[0045] Example 2: Pasteurized Akkermansia muciniphila sample preparation

[0046] The Akkermansia muciniphila culture solution prepared in Example 1 was centrifuged at 8000g / min for 10min, then suspended with sterile PBS, repeated centrifugation and washed three times, and the concentration was adjusted to 10 with sterile PBS. 9 CFU / mL, and then placed in a 70°C water bath for 30 minutes to obtain a pasteurized Akkermansia muciniphila suspension.

Embodiment 3

[0047] Example 3: Use of live and pasteurized Akkermansia muciniphila in reducing serum uric acid in mice

[0048] Thirty-two healthy male ICR mice weighing 25-28 g were selected, and after 1 week of adaptive culture, they were randomly divided into 4 groups, namely the blank group (CON), the hyperuricemia model group (Model), and the live mucotropin group. Akkermansiae intervention group (L-AKK) and pasteurized Akkermansia muciniphila intervention group (P-AKK). Except for the blank group (normal diet), the other groups (20% yeast extract feed) were given 100 mg / kg by gavage every morning 体重 of hypoxanthine and 280mg / kg 体重 6 hours after gavage in the morning, the blank group and model group were gavaged with sterile PBS, and L-AKK and P-AKK were gavage with live and pasteurized Akkermansia proteophila, respectively. The experimental groups and treatment methods are shown in Table 1; among them, drugs such as sodium carboxymethyl cellulose, potassium oxonate, hypoxanthine ar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of ackermania muciniphila in relieving hyperuricemia, and belongs to the technical field of microorganisms. The invention provides a new application of live and pasteurized ackermania proteinophila in the aspect of preventing and / or treating hyperuricemia. Live or pasteurized Ackermania proteinophila can reduce the level of serum uric acid, reduce the activity of xanthine oxidase (XOD) of the liver and reduce the synthesis of uric acid; the pathological injury of kidneys and intestinal tracts can be relieved; reabsorption of uric acid is reduced, and uric acid excretion is promoted; the expression of intestinal tight junction protein is promoted, the intestinal barrier is maintained, and the content of short-chain fatty acid in the intestinal tract is increased. The active or pasteurization inactivated Ackermania muciniphila provided by the invention can replace or partially replace the existing compound drugs, and has a wide application prospect.

Description

technical field [0001] The invention relates to the application of Akkermansia muciniphila in relieving hyperuricemia, and belongs to the technical field of microorganisms. Background technique [0002] Hyperuricemia is caused by excessive uric acid synthesis or too little excretion due to the disorder of purine metabolism in the body. In recent years, with the improvement of people's living standards and the increase in the intake of purine-rich foods, the incidence of hyperuricemia has been increasing, and the age of onset of the disease has also decreased. Since hyperuricemia is highly correlated with gout, it is of great significance to explore effective methods to control hyperuricemia. At present, the drugs for the treatment of hyperuricemia include febuxostat (xanthine oxidase inhibitor), probenecid (uric acid excretion agent) and rasburicase (decomposition of uric acid), etc. Most of these drugs have side effects, mainly Focus on liver and kidney function damage an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/74A61P19/06C12N1/20C12R1/01
CPCC12N1/20A61K35/74A61P19/06Y02A50/30
Inventor 夏效东张里华秦宁波任晓萌
Owner DALIAN POLYTECHNIC UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap